D. E. Shaw & Co. Inc. Sells 306,777 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

D. E. Shaw & Co. Inc. lessened its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 37.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 518,340 shares of the biopharmaceutical company's stock after selling 306,777 shares during the period. D. E. Shaw & Co. Inc. owned 0.78% of Celldex Therapeutics worth $13,098,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Deep Track Capital LP bought a new stake in Celldex Therapeutics during the 4th quarter worth about $38,919,000. Price T Rowe Associates Inc. MD lifted its position in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after purchasing an additional 676,771 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Celldex Therapeutics by 46.5% during the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after purchasing an additional 193,093 shares during the last quarter. Crestline Management LP increased its holdings in shares of Celldex Therapeutics by 114.0% in the fourth quarter. Crestline Management LP now owns 295,354 shares of the biopharmaceutical company's stock valued at $7,464,000 after purchasing an additional 157,366 shares in the last quarter. Finally, Eversept Partners LP raised its position in Celldex Therapeutics by 27.4% in the 4th quarter. Eversept Partners LP now owns 719,836 shares of the biopharmaceutical company's stock worth $18,190,000 after purchasing an additional 154,934 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Canaccord Genuity Group started coverage on Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. UBS Group lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Morgan Stanley dropped their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $19.62 on Wednesday. The firm has a market cap of $1.30 billion, a PE ratio of -7.63 and a beta of 1.39. The business's 50 day simple moving average is $18.93 and its 200 day simple moving average is $22.73. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, equities research analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.